StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Analysts at StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.88 on Friday. The business’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.17. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $6.37.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EGRX. Jane Street Group LLC acquired a new stake in Eagle Pharmaceuticals during the third quarter worth $96,000. DGS Capital Management LLC raised its stake in shares of Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $453,000. Finally, RBF Capital LLC boosted its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares in the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.